Del Parigi, Angelo
Tang, Wenbo
Liu, Dacheng
Lee, Christopher
Pratley, Richard
Article History
First Online: 20 May 2019
Compliance with Ethical Standards
:
: The studies were sponsored by the Boehringer Ingelheim and Eli Lilly and Company Diabetes Alliance; this analysis was supported by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI). The authors received no direct compensation related to the development of the manuscript. Writing support was provided by Jennifer Garrett, MBBS, of Envision Scientific Solutions, which was contracted and compensated by BIPI for this service. Open access was funded by BIPI.
: Richard Pratley has received research funding from Lexicon Pharmaceuticals, Lilly, Merck, Novo Nordisk, Sanofi Aventis US, LLC, and Takeda; speaker fees from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, and Takeda; and consultancy fees from AstraZeneca, Boehringer Ingelheim, Janssen Scientific Affairs, LLC, Ligand Pharmaceuticals, Inc., Lilly, Merck, Novo Nordisk, Sanofi Aventis US, LLC, and Takeda. All honoraria and fees are directed to a non-profit organization; he received no direct compensation. Dacheng Liu and Wenbo Tang are employees of Boehringer Ingelheim. Angelo Del Parigi and Christopher Lee were employees of Boehringer Ingelheim at the time these studies were conducted.
: In the studies analyzed, all procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the studies.
: This work was previously presented as a poster at the American Association of Clinical Endocrinologists (AACE) 26th Annual Scientific and Clinical Congress, Austin, TX, USA, 3–7 May 2017.